Participants
In Part 1 of the study, a total of 180 participants aged ≥18 years were randomly assigned to receive placebo or 1 dose of mRNA-1010 (50 µg, 100 µg, or 200 µg) between July 6, 2021, and August 18, 2021 (Fig. 